JP2025510512A5 - - Google Patents

Info

Publication number
JP2025510512A5
JP2025510512A5 JP2024550205A JP2024550205A JP2025510512A5 JP 2025510512 A5 JP2025510512 A5 JP 2025510512A5 JP 2024550205 A JP2024550205 A JP 2024550205A JP 2024550205 A JP2024550205 A JP 2024550205A JP 2025510512 A5 JP2025510512 A5 JP 2025510512A5
Authority
JP
Japan
Prior art keywords
alkyl
stereoisomer
cycloalkyl
isotope
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510512A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/078288 external-priority patent/WO2023160672A1/en
Publication of JP2025510512A publication Critical patent/JP2025510512A/ja
Publication of JP2025510512A5 publication Critical patent/JP2025510512A5/ja
Pending legal-status Critical Current

Links

JP2024550205A 2022-02-25 2023-02-25 Lpa受容体活性と関連する状態の処置のための化合物および組成物 Pending JP2025510512A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2022077844 2022-02-25
CNPCT/CN2022/077844 2022-02-25
CNPCT/CN2022/094839 2022-05-25
CN2022094839 2022-05-25
CN2022117690 2022-09-08
CNPCT/CN2022/117690 2022-09-08
PCT/CN2023/078288 WO2023160672A1 (en) 2022-02-25 2023-02-25 Compounds and compositions for treating conditions associated with lpa receptor activity

Publications (2)

Publication Number Publication Date
JP2025510512A JP2025510512A (ja) 2025-04-15
JP2025510512A5 true JP2025510512A5 (cg-RX-API-DMAC7.html) 2026-03-04

Family

ID=85569993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550205A Pending JP2025510512A (ja) 2022-02-25 2023-02-25 Lpa受容体活性と関連する状態の処置のための化合物および組成物

Country Status (28)

Country Link
US (3) US11884627B2 (cg-RX-API-DMAC7.html)
EP (2) EP4482579B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510512A (cg-RX-API-DMAC7.html)
KR (1) KR20240154590A (cg-RX-API-DMAC7.html)
CN (1) CN119110795A (cg-RX-API-DMAC7.html)
AR (1) AR128613A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023225907A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253274A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024002532A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024011399A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240353A (cg-RX-API-DMAC7.html)
DK (1) DK4482579T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000165A (cg-RX-API-DMAC7.html)
ES (1) ES3070542T3 (cg-RX-API-DMAC7.html)
FI (1) FI4482579T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260420T1 (cg-RX-API-DMAC7.html)
IL (1) IL315171A (cg-RX-API-DMAC7.html)
LT (1) LT4482579T (cg-RX-API-DMAC7.html)
MA (1) MA68743B1 (cg-RX-API-DMAC7.html)
MX (1) MX2024010344A (cg-RX-API-DMAC7.html)
PE (1) PE20242277A1 (cg-RX-API-DMAC7.html)
PL (1) PL4482579T3 (cg-RX-API-DMAC7.html)
PT (1) PT4482579T (cg-RX-API-DMAC7.html)
RS (1) RS67975B1 (cg-RX-API-DMAC7.html)
SI (1) SI4482579T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600170T1 (cg-RX-API-DMAC7.html)
TW (1) TW202342017A (cg-RX-API-DMAC7.html)
WO (1) WO2023160672A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342017A (zh) * 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與lpa受體活性相關的病狀的化合物及組合物
JP2025540714A (ja) * 2022-11-24 2025-12-16 ローツェ・バイオ・インコーポレイテッド Lpa受容体活性と関連する状態を処置するための化合物および組成物

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2300699A (en) 1998-02-17 1999-08-30 Ono Pharmaceutical Co. Ltd. Amidino derivatives and drugs containing the same as the active ingredient
US20030134853A1 (en) * 2001-09-26 2003-07-17 Priestley Eldon Scott Compounds useful for treating hepatitis C virus
US7285680B2 (en) 2002-05-28 2007-10-23 Ono Pharmaceutical Co., Ltd. β-alanine derivatives and the use thereof
EP1553075B1 (en) 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
TW200521108A (en) 2003-12-19 2005-07-01 Ono Pharmaceutical Co Compounds having lysophosphatidic acid receptor(LPA)-antagonizing effect and their use
FR2874379B1 (fr) 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
MX2007001943A (es) 2004-08-17 2007-05-09 Galderma Res & Dev Nuevos compuestos biaromaticos activadores de los receptores del tipo receptor activado del proliferador de peroxisoma (ppar) y su uso en composiciones cosmeticas o farmaceuticas.
US20070032488A1 (en) 2005-08-05 2007-02-08 Genelabs Technologies, Inc. 6-Membered aryl and heteroaryl derivatives for treating viruses
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
WO2012078593A2 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US20130122297A1 (en) 2011-10-24 2013-05-16 Northwestern University Molecular gauge blocks for building on the nanoscale
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
SG11201407220YA (en) 2012-06-20 2014-12-30 Hoffmann La Roche N-alkyltriazole compounds as lpar antagonists
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
PT3013796T (pt) 2013-06-27 2020-03-26 Lg Chemical Ltd Derivados biarílicos como agonistas de gpr120
US10099981B2 (en) 2015-03-31 2018-10-16 University Of Georgia Research Foundation, Inc. Methods for meta-arylation of aromatic alcohols
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2019041340A1 (en) 2017-09-04 2019-03-07 Eli Lilly And Company LYSOPHOSPHATIDE ACID RECEPTOR 1 RECEPTOR INHIBITORS (LPAR1)
JP7369125B2 (ja) 2017-12-19 2023-10-25 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのイソキサゾールo-架橋カルバモイルシクロヘキシル酸
JP7202383B2 (ja) 2017-12-19 2023-01-11 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのピラゾールo-架橋カルバモイルシクロヘキシル酸
WO2019126087A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
CA3085561A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
JP7212047B2 (ja) 2017-12-19 2023-01-24 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
CN111712492B (zh) 2017-12-19 2024-05-31 百时美施贵宝公司 作为lpa拮抗剂的环己基酸三唑唑类
ES2962367T3 (es) 2017-12-19 2024-03-18 Bristol Myers Squibb Co Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA)
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
KR102725744B1 (ko) 2017-12-19 2024-11-01 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아진
EP3807254A4 (en) * 2018-06-18 2022-03-23 Epigen Biosciences, Inc. HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
KR102800284B1 (ko) 2018-09-18 2025-04-23 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헵틸 산
JP7412424B2 (ja) 2018-09-18 2024-01-12 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのオキサビシクロ酸
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN111434653A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
CN111434655A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
US12466804B2 (en) 2019-06-18 2025-11-11 Bristol-Myers Squibb Company Cyclobutyl carboxylic acids as LPA antagonists
EP3986552B1 (en) 2019-06-18 2024-09-18 Bristol-Myers Squibb Company Isoxazole carboxylic acids as lpa antagonists
KR20220024548A (ko) 2019-06-18 2022-03-03 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 트리아졸 카르복실산
IL289951B2 (en) 2019-07-30 2025-10-01 Taisho Pharmaceutical Co Ltd Urea compound as an LPA1 receptor antagonist
US20230061417A1 (en) 2019-12-12 2023-03-02 Chiesi Farmaceutici S.P.A. Thienopyrimidine derivatives as lpa receptor 2 inhibitors
JP2023505703A (ja) 2019-12-12 2023-02-10 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Lpa受容体2阻害剤としての芳香族アミド誘導体
IL300525A (en) 2020-08-11 2023-04-01 Viva Star Biosciences Ltd Triazole-pyridinyl-substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists
WO2022083703A1 (en) 2020-10-22 2022-04-28 Lhotse Bio, Inc. Compounds and compositions for treating conditions associated with lpa receptor activity
WO2022100623A1 (zh) 2020-11-10 2022-05-19 武汉人福创新药物研发中心有限公司 氮取代杂环噻吩类化合物及其用途
WO2022100625A1 (zh) 2020-11-10 2022-05-19 武汉人福创新药物研发中心有限公司 氮取代氨基碳酸酯噻吩类化合物及其用途
CN114621135B (zh) 2020-12-11 2024-01-30 上海拓界生物医药科技有限公司 一种lpa1小分子拮抗剂
US20240190860A1 (en) 2021-03-24 2024-06-13 Chiesi Farmaceutici S.P.A. 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors
KR20240038004A (ko) 2021-07-20 2024-03-22 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 Lpa1 소분자 길항제
JP2024540937A (ja) 2021-10-21 2024-11-06 ローツェ・バイオ・インコーポレイテッド Lpa受容体活性に関連する状態を処置するための化合物および組成物
TW202342017A (zh) * 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與lpa受體活性相關的病狀的化合物及組合物
JP2025540714A (ja) 2022-11-24 2025-12-16 ローツェ・バイオ・インコーポレイテッド Lpa受容体活性と関連する状態を処置するための化合物および組成物

Similar Documents

Publication Publication Date Title
JP2021508686A5 (cg-RX-API-DMAC7.html)
JP2021507895A5 (cg-RX-API-DMAC7.html)
JP2021507896A5 (cg-RX-API-DMAC7.html)
HRP20211918T1 (hr) Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti
ES2628953T3 (es) Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B
JP2022500470A5 (cg-RX-API-DMAC7.html)
JP2022500473A5 (cg-RX-API-DMAC7.html)
JP2024517942A5 (cg-RX-API-DMAC7.html)
JP2023541522A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2022500469A5 (cg-RX-API-DMAC7.html)
US20110064673A1 (en) New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them
JP2007269797A5 (cg-RX-API-DMAC7.html)
JP2022544714A5 (cg-RX-API-DMAC7.html)
JP2021507900A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JP2020520926A5 (cg-RX-API-DMAC7.html)
JP2024133626A (ja) Peg化されたカルフィルゾミブ化合物の安定組成物
JP2024534840A5 (cg-RX-API-DMAC7.html)
JP2024542128A5 (cg-RX-API-DMAC7.html)
JP2024543013A5 (cg-RX-API-DMAC7.html)
RU2007116987A (ru) Новые соединения
AU2021328979A1 (en) Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof
JP2022552019A5 (cg-RX-API-DMAC7.html)